Nanomedicine in rheumatology: A new field in the diagnosis and therapy of rheumatic diseases
Journal Title: International Journal of Clinical Rheumatology - Year 2018, Vol 13, Issue 1
Abstract
Nanomedicine is a prolific and vastly expanding field of medicine rendering important new avenues to improve diagnosis and treatment of human maladies. However, safety of the nanomaterials and therapeutic agents must be carefully considered. In the forthcoming future, more anti-inflammatory drugs targeting cytokines will hopefully be nanodeveloped to treat, making ‘target-to-treat’ as important as the emerging ‘treat-to-target’ strategy. Nanomedicines that reduce the dosage, frequency and adverse-effects of the anti-inflammatory drugs used nowadays will possibly move to clinical practice.
Authors and Affiliations
Tamer A. Gheita, Sanaa A Kenawy
Keywords
Related Articles
- EP ID EP604302
- DOI -
- Views 56
- Downloads 0
Serum vitamin D in Egyptian patients with systemic lupus erythematous and its association with lupus nephritis
Aim: To assess VD levels in serum of patients with LN in comparison with patients with extra-renal lupus and healthy controls, and to assess the relation between VD levels and the various clinical and laboratory disease...
The correlation between blood lead levels and knee osteoarthritis: a preliminary Egyptian study
Background: Lead is a common ubiquitous environmental pollutant. The increasing prevalence of knee Osteoarthritis (OA) among young patients is suggestive of a possible contribution of environmental factors such as lead....
Nanomedicine in rheumatology: A new field in the diagnosis and therapy of rheumatic diseases
Nanomedicine is a prolific and vastly expanding field of medicine rendering important new avenues to improve diagnosis and treatment of human maladies. However, safety of the nanomaterials and therapeutic agents must be...
Lower ratings of pain intensity in older adults lead to underestimation of disease activity in patients with rheumatoid arthritis
Background: To investigate the influence of age on the components of the 28-joint Disease Activity Score (DAS28)-C-Reactive Protein (CRP) in patients with Rheumatoid Arthritis (RA) and whether DAS28-CRP can be equally in...
Adalimumab induced chronic interstitial nephritis: a controlled blinded trial in mice
Background: Adalimumab is a known drug modifying agent for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) treatment. However little is known about the risk of nephrotoxicity. To determine whether the i...